Pamiparib: First Approval

2021/07/01 by Anthony Markham · 26 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #PARP inhibition in cancer therapy #BRCA gene mutations in cancer #Ovarian cancer diagnosis and treatment

paper · doi:10.1007/s40265-021-01552-8

Cited by

• PARPs and PARP inhibitors: molecular mechanisms and clinical applications
• PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. [europepmc]
• Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. [europepmc]
• Opinion: PARP inhibitors in cancer-what do we still need to know? [europepmc]
• A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. [europepmc]
• Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. [europepmc]
• Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. [europepmc]
• Small molecule inhibitors targeting the cancers. [europepmc]
• Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling. [europepmc]
• Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. [europepmc]
• Targeting the DNA damage response for cancer therapy. [europepmc]
• Targeting Breast Cancer: An Overlook on Current Strategies. [europepmc]
• Human PARP1 substrates and regulators of its catalytic activity: An updated overview. [europepmc]
• Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition. [europepmc]
• Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options. [europepmc]
• A new wave of innovations within the DNA damage response. [europepmc]
• Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial. [europepmc]
• New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives. [europepmc]
• ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. [europepmc]
• Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader. [europepmc]
• Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. [europepmc]
• Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging. [europepmc]
• Discovery of Fused Isoquinolinone/Triazole as a Scaffold for Tankyrase and PARP Inhibition. [europepmc]
• PARPs and PARP inhibitors: molecular mechanisms and clinical applications. [europepmc]
• PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge. [europepmc]
• Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [europepmc]